Albany, NY (PRWEB) October 24, 2013
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective
Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.
To check out the complete table of contents, visit http://www.marketresearchreports.biz/analysis-details/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-and-cells-emerging-opportunities-for-the-biopharmaceutical-industry.
Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.
The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.
Copyright©2012 Vocus, Inc.
All rights reserved